Abstract
The reason why NSAIDs injure the small intestinal mucosa, but spare the duodenal mucosa is unknown. The short‐chain fatty acid receptor GRP43 is expressed in 5‐HT containing enterochromaffin cells, and a selective GPR43 agonist phenylacetamide‐1 (PA1) increases duodenal HCO3‐ secretion (DBS) via 5HT4 receptor activation. We hypothesized that GPR43 activation modulates duodenal mucosal defenses via 5‐HT release in an NSAID‐induced intestinal injury model.We measured DBS with pH and CO2 electrodes in vivo through a duodenal loop, perfused with PA1 (0.1 ‐ 10 µM) while measuring released 5‐HT in the portal vein (PV). Intestinal injury was induced by indomethacin (IND, 10 mg/kg, sc) with or without PA1 (0.1 ‐ 1 mg/kg, ig), the 5HT3 antagonist ondansetron (Ond, 3 mg/kg, ip), omeprazole (OPZ, 10 mg/kg, ig), or atropine (10 mg/kg, ig).Luminal perfusion with PA1 dose‐dependently increased DBS accompanied by 5‐HT release into PV. IND induced small intestinal ulcers with duodenal sparing. PA1 + IND dose‐dependently induced duodenal lesions, whereas PA1 alone had no effect. PA1 + IND‐induced duodenal lesions were inhibited by Ond or OPZ, but not by atropine. Non‐duodenal intestinal lesions were reduced by Ond or atropine, but not by OPZ as previously reported.These results suggest that although GPR43 activation enhances mucosal defenses by increased DBS via 5HT4 activation, GPR43 activation combined with COX inhibition may increase the vulnerability of the duodenal mucosa to gastric acid via 5HT3 activation.Grant Funding Source: Supported by VA Merit Review, NIH R01 DK54221
Published Version
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call